ConductScience.org, home

Paper42581900

Precision oncology in the treatment of patients with bone sarcomas: an up-to-date narrative review.

Yarar S and 1 other. Explor Target Antitumor Ther, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Precision oncology in the treatment of patients with bone sarcomas: an up-to-date narrative review. Papers, record 42581900. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42581900

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Precision oncology in the treatment of patients with bone sarcomas: an up-to-date narrative review.
PubMed
Journal
Explor Target Antitumor Ther
PubMed
Year
2026
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-08-13
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Yarar SSude
2Tsagkozis PPanagiotishttps://orcid.org/0000-0002-6631-2053

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References132

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
141037832HDAC inhibitor (SAHA) enhances B7-H3-specific CAR T cell cytotoxic efficacy against chondrosarcoma cells and prolongs survival in an orthotopic mouse model.Transl Oncol2025https://conductscience.org/library/papers/41037832PubMed
240422235Modeling Tumor Microenvironment Complexity In Vitro: Spheroids as Physiologically Relevant Tumor Models and Strategies for Their Analysis.Cells2025https://conductscience.org/library/papers/40422235PubMed
328133974Novel therapeutic approaches in chondrosarcoma.Future Oncol2017https://conductscience.org/library/papers/28133974PubMed
428707624Three-dimensional (3D) culture in sarcoma research and the clinical significance.Biofabrication2017https://conductscience.org/library/papers/28707624PubMed
530006631Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness.Sci Rep2018https://conductscience.org/library/papers/30006631PubMed
626962160Chemotherapy for Bone Sarcoma in Adults.J Oncol Pract2016https://conductscience.org/library/papers/26962160PubMed
734535153The basic characteristics of extracellular vesicles and their potential application in bone sarcomas.J Nanobiotechnology2021https://conductscience.org/library/papers/34535153PubMed
826304877Osteosarcoma: Current Treatment and a Collaborative Pathway to Success.J Clin Oncol2015https://conductscience.org/library/papers/26304877PubMed
939622151Patient-derived tumor organoids: A preclinical platform for personalized cancer therapy.Transl Oncol2025https://conductscience.org/library/papers/39622151PubMed
1032483734Using Liquid Biopsy in the Treatment of Patient with OS.Adv Exp Med Biol2020https://conductscience.org/library/papers/32483734PubMed
1134938658Metabolic Pathways and Targets in Chondrosarcoma.Front Oncol2021https://conductscience.org/library/papers/34938658PubMed
1227447864Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics.Oncotarget2017https://conductscience.org/library/papers/27447864PubMed
1340426987Biomarker-Driven Approaches to Bone Metastases: From Molecular Mechanisms to Clinical Applications.Biomedicines2025https://conductscience.org/library/papers/40426987PubMed
1436046479Clinical implementation of plasma cell-free circulating tumor DNA quantification by digital droplet PCR for the monitoring of Ewing sarcoma in children and adolescents.Front Pediatr2022https://conductscience.org/library/papers/36046479PubMed
1533894338Osteosarcoma, chondrosarcoma and Ewing sarcoma: Clinical aspects, biomarker discovery and liquid biopsy.Crit Rev Oncol Hematol2021https://conductscience.org/library/papers/33894338PubMed
1635746359A Smarter Health through the Internet of Surgical Things.Sensors (Basel)2022https://conductscience.org/library/papers/35746359PubMed
1732078813Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial.Lancet Oncol2020https://conductscience.org/library/papers/32078813PubMed
1837174021Molecular In-Depth Characterization of Chondrosarcoma for Current and Future Targeted Therapies.Cancers (Basel)2023https://conductscience.org/library/papers/37174021PubMed
1931970591Targeting the undruggable: exploiting neomorphic features of fusion oncoproteins in childhood sarcomas for innovative therapies.Cancer Metastasis Rev2019https://conductscience.org/library/papers/31970591PubMed
2041749815From Bench to Bedside: Advancements in Precision Oncology and Drug Discovery for Osteosarcoma.Cancers (Basel)2026https://conductscience.org/library/papers/41749815PubMed

See all 132 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42581900

GET https://conductscience.org/api/papers/v1/42581900/references?page=2